Unknown PHASE2 INTERVENTIONAL 1-arm NCT02893306

MSC Administration for the Management of Type 1 Diabetic Patients (DMT1-MSC)

Phase 2 Study of Intravenous Administration of Allogeneic Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus.

Sponsor: Clinica Alemana de Santiago

Conditions Type 1 Diabetes Mellitus

Interventions MSCs

Updated 6 times since 2017 Last updated: Sep 1, 2016 Started: Mar 31, 2012 Primary completion: Mar 31, 2017 Completion: Mar 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Type 1 Diabetes Mellitus, this trial is ongoing. The trial is conducted by Clinica Alemana de Santiago and has accumulated 6 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Oct 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status
Jun 2018 — Oct 2018 [monthly]

Active Not Recruiting PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clinica Alemana de Santiago
Universidad del Desarrollo

Data source: Universidad del Desarrollo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Santiago, Chile